Identification and Multicentral Clinical Validation of Plasma Diagnostic Biomarkers for Gastric Cancer Based on Wide-targeted and Targeted Metabolomics
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,706
- 试验地点
- 4
- 主要终点
- Plasma metabolite content
研究概览
简要总结
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction with both broad-spectrum and targeted metabolomics approaches. The goal is to construct a dedicated plasma metabolite database for gastric cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early gastric cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of gastric cancer.
详细描述
Firstly, a wide-targeted metabolomic measurement will be conducted on plasma samples from the discovery cohort to identify potential metabolite candidate markers and construct a gastric cancer patient-specific metabolite database with extensive metabolite information.
Secondly, a more precise targeted metabolomic measurement will be conducted in the modeling cohort. Bioinformatics methods will be used to conduct an in-depth analysis of a wide range of metabolite information to screen out metabolic marker combinations with high gastric cancer-specific diagnostic efficacy.
Ultimately, an external validation cohort will be introduced to validate these metabolic biomarkers, aiming to ensure reliability and stability across different patient populations.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Confirmed diagnosis of gastric cancer or benign gastric diseases through gastroscopy and pathological examination.
- •Collection of plasma samples prior to surgical treatment.
- •Availability of complete clinical data.
排除标准
- •Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
- •Coexistence of other systemic tumors.
- •Absence of plasma sample collection before surgical treatment.
- •Incomplete clinical data.
- •Pregnancy status.
结局指标
主要结局
Plasma metabolite content
时间窗: Before receiving treatment for gastric cancer
The outcome will be tested by metabolomics detection technology based on mass spectrometry
次要结局
未报告次要终点
研究者
Min Li
Deputy Director of Science and Technology Department
Beijing Friendship Hospital